InsidersTradesSigma
Follow the Axogen, Inc. stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Axogen, Inc. has logged 213 reports. Market capitalisation: €2.8bn. The latest transaction was filed on 4 September 2026 (Cession). Among the most active insiders: DeVinney Erick Wayne. All data is accessible without an account.
213
Insider Decl.
n/a
Thresholds
€174,594
3 ops.
Buy Volume
€10m
37 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Axogen, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$53.90.
42Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 21,077 of 29,063 companies
36.6
score / 100
Value34
Quality39
FCF yld-0.2%
Earn yld-0.6%
EV/EBITDA·
ROE-18%
Gross mgn74%
Net mgn-7.0%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
Declarations213 total
3,500 shares@ US$49.6970.0063% mcap39.9% of flowCommon StockSEC:0000805928-26-000101:0
67,500 shares@ US$8.160.021% mcap12.4% of flowCommon StockSEC:0000805928-26-000099:0
67,500 shares@ US$47.3450.12% mcap72.2% of flowCommon StockSEC:0000805928-26-000099:1
13,353 shares@ US$14.850.0076% mcap13.7% of flowCommon StockSEC:0000805928-26-000098:0
13,353 shares@ US$48.4230.025% mcap44.7% of flowCommon StockSEC:0000805928-26-000098:1
13,353 shares@ US$48.220.025% mcap100.0% of flowCommonSEC144:0001950047-26-007960
14,150 shares@ US$45.2980.026% mcap79.1% of flowCommon StockSEC:0000805928-26-000096:0
67,500 shares@ US$46.430.13% mcap100.0% of flowCOMMONSEC144:0001950047-26-007883
14,150 shares@ US$44.350.026% mcap100.0% of flowCommonSEC144:0001950047-26-007808
18,867 sharesCommon StockSEC:0000805928-26-000078:0
14,150 sharesCommon StockSEC:0000805928-26-000079:0
14,150 sharesCommon StockSEC:0000805928-26-000080:0
14,150 sharesCommon StockSEC:0001400568-26-000013:0
14,150 sharesCommon StockSEC:0001410781-26-000006:0
14,150 sharesCommon StockSEC:0000805928-26-000076:0
14,150 sharesCommon StockSEC:0000805928-26-000077:0
1,647 shares@ US$14.850.0009% mcap4.7% of flowCommon StockSEC:0001400568-26-000009:0
1,647 shares@ US$42.600.0027% mcap13.4% of flowCommon StockSEC:0001400568-26-000009:1
4,000 shares0Common StockSEC:0000805928-26-000047:0
6,363 shares0Common StockSEC:0000805928-26-000048:0
33,780 shares0Common StockSEC:0000805928-26-000043:0
33,780 shares0Common StockSEC:0000805928-26-000042:0
17,453 shares0Common StockSEC:0000805928-26-000038:0
17,500 shares0Common StockSEC:0000805928-26-000032:0
25 of 213 declarations
关于 Axogen, Inc.
Axogen, Inc.是一家美国医疗科技公司，在纳斯达克市场（美国）上市，专注于周围神经再生和修复。Axogen并非作为一家广泛的制药公司参与竞争，而是在一个专业的 хирур外科领域运营：在创伤性损伤或手术损伤后恢复周围神经功能。该公司在明尼苏达州注册成立，总部位于佛罗里达州，在俄亥俄州和德克萨斯州设有加工、仓储和分销设施。因此，其地理足迹主要以美国为中心，公司绝大部分收入来自美国客户。([ir.axogeninc.com](https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-25-000017/axgn-20241231.htm)) Axogen的商业模式以周围神经再生和修复技术的研究、开发和商业化为中心。其核心产品组合包括Avance® Nerve Graft、Axoguard Nerve Connector®、Axoguard Nerve Protector®、Axoguard HA+ Nerve Protector™、Axoguard Nerve Cap®和Avive+ Soft Tissue Matrix™。这些产品涵盖了神经手术的不同步骤，从连接神经间隙到保护修复的神经以及支持软组织管理。公司报告为一个单一运营部门，这突显了其高度集中的战略以及专注于一个临床类别而非多个终端市场。([ir.axogeninc.com](https://ir.axogeninc.com/sec-filings/all-sec-filings/content/0000805928-25-000017/axgn-20241231.htm)) 从竞争角度来看，Axogen在一个相对渗透不足但临床和报销进展日益验证的市场中定位为品类专家。其长期机会取决于外科医生的采纳、支付方的覆盖以及周围神经修复作为标准护理的持续临床接受度。在2025年，Axogen强调了使用合成导管和同种异体移植物进行周围神经修复的商业覆盖和报销的扩大，这是市场发展的重要指标，也是未来利用的潜在驱动力。([globenewswire.com](https://www.globenewswire.com/news-release/2026/02/24/3243354/0/en/axogen-inc-reports-fourth-quarter-and-full-year-2025-financial-results.html)) 公司近期里程碑尤其重要。2024年11月，FDA接受了Axogen的Avance® Nerve Graft的BLA申请，并将PDUFA目标日期定为2025年9月5日。2025年12月3日，FDA批准了BLA，标志着公司监管方面的一个重要转折点。2026年1月，Axogen完成了一次超额公开发行，净收益达133.3 million美元；其中一部分资金用于全额偿还并终止其Oberland贷款融资，从而增强了资产负债表。对于投资者而言，Axogen代表了一个专注于美国纳斯达克上市的医疗保健故事，具有重要的监管催化剂、专业化的产品特许经营权和不断增长的报销背景。([globenewswire.com](https://www.globenewswire.com/news-release/2025/08/05/3127191/0/en/Axogen-Inc-Reports-Second-Quarter-2025-Financial-Results.html))
